title: Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
abstract: Antioestrogen treatment by tamoxifen is a well-established adjuvant therapy for oestrogen receptor-alpha (ERalpha) positive breast cancer. Despite ERalpha expression some tumours do not respond to tamoxifen and we therefore delineated the potential link between the cell cycle regulator and ERalpha co-factor, cyclin D1, and tamoxifen response in a material of 167 postmenopausal breast cancers arranged in a tissue array. The patients had been randomised to 2 years of tamoxifen treatment or no treatment and the median follow-up time was 18 years. Interestingly in the 55 strongly ERalpha positive samples with moderate or low cyclin D1 levels, patients responded to tamoxifen treatment whereas the 46 patients with highly ERalpha positive and cyclin D1 overexpressing tumours did not show any difference in survival between tamoxifen and no treatment. Survival in untreated patients with cyclin D1 high tumours was slightly better than for patients with cyclin D1 low/moderate tumours. However, there was a clearly increased risk of death in the cyclin D1 high group compared to an age-matched control population. Our results suggest that cyclin D1 overexpression predicts for tamoxifen treatment resistance in breast cancer, which is line with recent experimental data using breast cancer cell lines and overexpression systems.
authors.affiliation: Division of Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-20502 Malmö, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Stendahl
authors.forename: A
authors.initials: A
authors.lastname: Kronblad
authors.forename: L
authors.initials: L
authors.lastname: Rydén
authors.forename: S
authors.initials: S
authors.lastname: Emdin
authors.forename: N O
authors.initials: NO
authors.lastname: Bengtsson
authors.forename: G
authors.initials: G
authors.lastname: Landberg
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D019938:Cyclin D1 / Q000032:analysis / Q000096:biosynthesis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D017698:Postmenopause; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use*; D015854:Up-Regulation
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019938:Cyclin D1